Portage Biotech Ownership
| PRTG Stock | USD 4.87 0.15 3.18% |
Shares in Circulation | First Issued 2000-12-31 | Previous Quarter 989.2 K | Current Value 1 M | Avarage Shares Outstanding 3.5 M | Quarterly Volatility 5.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Portage |
Portage Stock Ownership Analysis
About 30.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.97. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Portage Biotech recorded earning per share (EPS) of 24.4. The entity last dividend was issued on the 4th of June 2020. The firm had 1:20 split on the 15th of August 2024. Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. Portage Biotech is traded on NASDAQ Exchange in the United States. To find out more about Portage Biotech contact MD MBA at 203 221 7378 or learn more at https://www.portagebiotech.com.Besides selling stocks to institutional investors, Portage Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Portage Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Portage Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Portage Biotech Quarterly Liabilities And Stockholders Equity |
|
About 30.0% of Portage Biotech are currently held by insiders. Unlike Portage Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Portage Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Portage Biotech's insider trades
Portage Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Portage Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Portage Biotech backward and forwards among themselves. Portage Biotech's institutional investor refers to the entity that pools money to purchase Portage Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | The Toronto-dominion Bank | 2024-06-30 | 7.0 | Qube Research & Technologies | 2024-06-30 | 4.0 | Brown Brothers Harriman & Co | 2024-06-30 | 0.0 | Royal Bank Of Canada | 2024-06-30 | 0.0 | Sigma Planning Corp | 2024-06-30 | 0.0 | Beacon Investment Advisory Services, Inc. | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Lakeview Capital Partners, Llc | 2024-09-30 | 98.5 K | Ieq Capital, Llc | 2024-06-30 | 16.6 K |
Portage Biotech Outstanding Bonds
Portage Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Portage Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Portage bonds can be classified according to their maturity, which is the date when Portage Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Portage Biotech Corporate Filings
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
6K | 4th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 23rd of August 2024 Other Reports | ViewVerify | |
| 14th of August 2024 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 24.4 | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.